H.C. Wainwright raised the firm’s price target on Kazia Therapeutics (KZIA) to $18 from $13 and keeps a Buy rating on the shares. The company presented “encourating” results from its Phase 1 study of paxalisib for the treatment of triple-negative breast cancer, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Kazia Therapeutics Unveils Promising Paxalisib Data at Breast Cancer Symposium
- Kazia Therapeutics announces presentation from paxalisib studies
- Kazia Therapeutics Secures $46.5 Million Through Private Placement to Address Nasdaq Compliance
- Kazia Therapeutics Secures $50 Million in Private Placement to Advance Cancer Drug Development
- Kazia Therapeutics trading resumes